212 related articles for article (PubMed ID: 37069690)
1. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo.
Benvenuto M; Angiolini V; Focaccetti C; Nardozi D; Palumbo C; Carrano R; Rufini A; Bei R; Miele MT; Mancini P; Barillari G; Cirone M; Ferretti E; Tundo GR; Mutti L; Masuelli L; Bei R
Biol Direct; 2023 Apr; 18(1):17. PubMed ID: 37069690
[TBL] [Abstract][Full Text] [Related]
2. The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
Liu N; Huang H; Xu L; Hua X; Li X; Liu S; Yang C; Zhao C; Zhao C; Li S; Dou QP; Liu J
Toxicol Lett; 2014 Jan; 224(3):333-40. PubMed ID: 24291039
[TBL] [Abstract][Full Text] [Related]
3. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
Xu D; Liang SQ; Yang H; Lüthi U; Riether C; Berezowska S; Marti TM; Hall SRR; Bruggmann R; Kocher GJ; Schmid RA; Peng RW
Br J Cancer; 2018 Jul; 119(1):65-75. PubMed ID: 29921948
[TBL] [Abstract][Full Text] [Related]
4. Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response.
Dong X; Liao Y; Liu N; Hua X; Cai J; Liu J; Huang H
Mol Med Rep; 2016 Sep; 14(3):2679-84. PubMed ID: 27430733
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
6. Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line.
Masuelli L; Benvenuto M; Di Stefano E; Mattera R; Fantini M; De Feudis G; De Smaele E; Tresoldi I; Giganti MG; Modesti A; Bei R
Oncotarget; 2017 May; 8(21):34405-34422. PubMed ID: 28159921
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.
Benvenuto M; Ciuffa S; Focaccetti C; Sbardella D; Fazi S; Scimeca M; Tundo GR; Barillari G; Segni M; Bonanno E; Manzari V; Modesti A; Masuelli L; Coletta M; Bei R
Sci Rep; 2021 Sep; 11(1):19051. PubMed ID: 34561494
[TBL] [Abstract][Full Text] [Related]
9. Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
Cerruti F; Jocollè G; Salio C; Oliva L; Paglietti L; Alessandria B; Mioletti S; Donati G; Numico G; Cenci S; Cascio P
Sci Rep; 2017 Dec; 7(1):17626. PubMed ID: 29247244
[TBL] [Abstract][Full Text] [Related]
10. Calcium silicate/bortezomib combinatory therapy for multiple myeloma.
Cao L; Gu H; Zhang Z; Zhang E; Chang J; Cai Z
J Mater Chem B; 2023 Mar; 11(9):1929-1939. PubMed ID: 36744994
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
12. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
[TBL] [Abstract][Full Text] [Related]
14. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Wang Y; Rishi AK; Puliyappadamba VT; Sharma S; Yang H; Tarca A; Dou QP; Lonardo F; Ruckdeschel JC; Pass HI; Wali A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):455-66. PubMed ID: 19960346
[TBL] [Abstract][Full Text] [Related]
15. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
16. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
[TBL] [Abstract][Full Text] [Related]
17. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Szulkin A; Nilsonne G; Mundt F; Wasik AM; Souri P; Hjerpe A; Dobra K
PLoS One; 2013; 8(6):e65903. PubMed ID: 23840376
[TBL] [Abstract][Full Text] [Related]
18. [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].
Jiang XX; Zhang QL; Chen XY; Wu WL; Shen ZX; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1215-9. PubMed ID: 19840453
[TBL] [Abstract][Full Text] [Related]
19. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
